Project Grant R21CA289927
Award Date
8/8/24
Completion Date
7/31/26
Dollars Obligated
$185K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $483,000.00 to Case Western Reserve University to conduct research on defining the role of single-cell heterogeneity in bacterial vaginosis (BV). The overarching goal is to identify aspects of diversity that impact BV and provide insights into new strategies for prevention, treatment, and diagnosis. The...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $630,506 to The Johns Hopkins University to develop and test a therapeutic vaccine against cervical cancer associated with variants of the human papillomavirus type 16 (HPV16). The primary goals are to: 1) characterize how different HPV16 variants evade immune system detection, 2) study the growth and tumor microenvironment of spontaneous cervical/vaginal cancers driven by HPV16...
This federal Project Grant award of $533,707, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how the human papillomavirus (HPV) evades the body's natural defenses and persists in infected cells. The primary goal is to elucidate the mechanism by which the HPV E7 oncoprotein activates the YAP1 signaling pathway, enabling HPV-infected cells to remain in the...
This $189,540 Project Grant award, funded by the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program, supports a study to elucidate racial and ethnic differences in the functional effects of the vaginal microbiome on ovarian cancer. The study, conducted by Duke University, will apply an untargeted metabolomics approach to compare metabolite profiles of cervicovaginal fluid samples from 120 ovarian cancer patients across Black, Hispanic, and White racial/ethnic groups....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $392,904 to the University of Rochester to investigate the influence of the cervicovaginal phageome (bacteriophage communities) on women's reproductive health, particularly for women living with HIV/AIDS. The overarching objectives are to: 1) Characterize the cervicovaginal phageome communities over time, 2) Examine the impact of HIV/AIDS and...
This Project Grant award of $3,381,578.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how human papillomavirus (HPV) proteins reprogram host cell signaling pathways. The research aims to determine how the degradation of the RB1 and PTPN14 tumor suppressors by high-risk HPV E7 proteins contributes to host cell reprogramming and cellular transformation. The award...
This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...
This Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $533,750.00 to the University of Florida to study the role of macrophages in the increased HIV risk associated with bacterial vaginosis (BV). The research aims to determine how a non-optimal vaginal microbiome affects the activation and "training" of macrophages towards an HIV-permissive phenotype. This will be...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico Health Sciences Center (UNM HSC) to conduct research on the mechanisms of papillomavirus tumor regression induced by MEK signaling inhibition. The 5-year project aims to understand how MEK inhibition reduces expression of the HPV oncogenes E6 and E7, leading to diminished keratinocyte proliferation and activation of innate immune responses to...
This federal Project Grant award of $397,772.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support the development of novel computational methods for profiling the cancer virome and analyzing microbial strain genetics in cancer-associated microbiomes. The primary objectives are to: 1) create computational tools to accurately identify and quantify viruses in shotgun metagenomes and metatranscriptomes, and 2) develop biostatistical methods to...